Eurofins Scientific

In FY2016, Eurofins Scientific generated approximately EUR 2.5 billion in revenue, operating more than 225 laboratories across 39 countries with over 22,000 staff. Adjusted EBITDA margin was 18.9%. The company's core verticals — food and feed testing, environmental testing, and pharmaceutical services — were growing, but Eurofins was significantly smaller than global TIC leaders SGS and Bureau Veritas. The global testing, inspection, and certification market remained highly fragmented, with thousands of small regional laboratories operating at 6-10x EBITDA multiples — creating a persistent acquisition pipeline for well-capitalized consolidators.

Under founder-CEO Gilles Martin, Eurofins executed an aggressive multi-year acquisition and build-out strategy to become the dominant laboratory testing network globally:

• Sustained acquisition pace: Completed approximately 27 acquisitions in 2016, accelerating to approximately 50-60 per year in 2017-2018, then maintaining 30-60 acquisitions annually through 2024. In FY2024, Eurofins closed 31 business combinations with pro-forma revenues of EUR 225 million at an average sales multiple of 1.5x and adjusted EBITDA multiple of 10.0x.
• Geographic market entry: Expanded from 39 countries (2016) to 62 countries (2024), entering and scaling in India, China, Brazil, Japan, and Southeast Asia where regulatory tightening was driving demand for third-party testing.
• Hub-and-spoke laboratory model: Concentrated complex, high-value analytical work in large hub laboratories while using smaller spoke labs and blood collection points for routine sample collection. Launched 301 start-up laboratories and 67 blood collection points since 2000, contributing EUR 629 million of revenue by FY2023.
• COVID-19 testing pivot (2020-2021): Rapidly scaled PCR testing capacity across its laboratory network, processing 40 million PCR tests in-house and supplying reagents to external labs. COVID testing and reagent revenue reached EUR 1.43 billion in FY2021, up from EUR 800+ million in FY2020.
• Reinvestment of COVID windfall: Channeled pandemic-driven cash flow into further acquisitions and laboratory automation, accelerating the build-out of the global network.

• Revenue growth: Total revenue grew from approximately EUR 2.5 billion (FY2016) to EUR 6,951 million (FY2024), a 174% increase representing approximately 14% CAGR over eight years.
• Laboratory network expansion: Scaled from approximately 225 laboratories in 39 countries (2016) to more than 900 laboratories in 62 countries (2024) across more than 1,000 legal entities.
• Headcount growth: Grew from approximately 22,000 staff (2016) to approximately 62,000 staff (2024).
• Margin expansion: Adjusted EBITDA margin expanded from 18.9% (FY2016) to 22.3% (FY2024), a gain of 340 basis points, reflecting scale economies and mix shift toward higher-margin testing.
• Cash generation improvement: Free cash flow to the firm (FCFF) reached EUR 801 million in FY2024, up 69% from EUR 474 million in FY2023.
• Post-COVID organic growth: After COVID testing revenue declined from EUR 1.43B (FY2021) to approximately EUR 20M (FY2023), core business organic growth of 7.1% in FY2023 fully compensated for the lost COVID revenue.
• Timeframe: FY2016-FY2024 (8 years of sustained execution).

• Founder-CEO Gilles Martin (approximately 35% ownership stake) provides long-term strategic commitment and alignment, eliminating short-term activist pressure.
• Hub-and-spoke laboratory model drives margin expansion from acquisitions — small acquired labs feed samples into larger, more efficient hub laboratories.
• Accreditation moats (ISO 17025, GLP, GMP) in each laboratory represent years of investment and create barriers to entry for new competitors.
• TIC market fragmentation provides a virtually unlimited acquisition pipeline at reasonable multiples (1.5x revenue, 10x EBITDA in FY2024).
• Regulatory tailwinds in food safety, environmental testing (e.g., PFAS contamination), and pharmaceutical development continue to expand the addressable market.